These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 22315489)

  • 1. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study.
    Della Porta MG; Picone C; Pascutto C; Malcovati L; Tamura H; Handa H; Czader M; Freeman S; Vyas P; Porwit A; Saft L; Westers TM; Alhan C; Cali C; van de Loosdrecht AA; Ogata K
    Haematologica; 2012 Aug; 97(8):1209-17. PubMed ID: 22315489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study.
    Ogata K; Della Porta MG; Malcovati L; Picone C; Yokose N; Matsuda A; Yamashita T; Tamura H; Tsukada J; Dan K
    Haematologica; 2009 Aug; 94(8):1066-74. PubMed ID: 19546439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells.
    Ogata K; Sei K; Saft L; Kawahara N; Porta MGD; Chapuis N; Yamamoto Y
    Leuk Res; 2018 Aug; 71():75-81. PubMed ID: 30025279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of Quantitative assessment of Myeloid Nuclear Differentiation Antigen expression and other flow cytometric parameters in the diagnosis of Myelodysplastic syndrome.
    Somasundaram V; Soni S; Chopra A; Rai S; Mahapatra M; Kumar R; Pati H
    Int J Lab Hematol; 2016 Apr; 38(2):141-50. PubMed ID: 26822549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translating the MDS flow cytometric score into clinical practice.
    Heron M; Dovern E; Bakker-Jonges LE; Posthuma EF; Brouwer RE; Smedts F; Batstra MR
    Cytometry B Clin Cytom; 2015; 88(3):207-9. PubMed ID: 25490972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostic significance of immunophenotyping of bone marrow cells in myelodysplastic syndrome without an increase of marrow blasts].
    Xu J; Zhang W; Liu Y; Wan SG; Sun XJ; Zhao H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1477-81. PubMed ID: 20030930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome.
    Stetler-Stevenson M; Arthur DC; Jabbour N; Xie XY; Molldrem J; Barrett AJ; Venzon D; Rick ME
    Blood; 2001 Aug; 98(4):979-87. PubMed ID: 11493442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Value of Flow Cytometry Standardized Using the European LeukemiaNet for Myelodysplastic Syndrome.
    Takeuchi A; Imataki O; Kubo H; Kondo A; Seo K; Uemura M; Yamaoka G; Murao K; Takeuchi A
    Acta Haematol; 2020; 143(2):140-145. PubMed ID: 31330512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
    Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
    Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.
    Westers TM; Cremers EM; Oelschlaegel U; Johansson U; Bettelheim P; Matarraz S; Orfao A; Moshaver B; Brodersen LE; Loken MR; Wells DA; Subirá D; Cullen M; Te Marvelde JG; van der Velden VH; Preijers FW; Chu SC; Feuillard J; Guérin E; Psarra K; Porwit A; Saft L; Ireland R; Milne T; Béné MC; Witte BI; Della Porta MG; Kern W; van de Loosdrecht AA;
    Haematologica; 2017 Feb; 102(2):308-319. PubMed ID: 27758818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of flow cytometric immunophenotyping in myelodysplastic syndromes.
    Pagnucco G; Giambanco C; Gervasi F
    Ann N Y Acad Sci; 2006 Nov; 1089():383-94. PubMed ID: 17261782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes.
    Cremers EM; Westers TM; Alhan C; Cali C; Visser-Wisselaar HA; Chitu DA; van der Velden VH; Te Marvelde JG; Klein SK; Muus P; Vellenga E; de Greef GE; Legdeur MC; Wijermans PW; Stevens-Kroef MJ; Silva-Coelho PD; Jansen JH; Ossenkoppele GJ; van de Loosdrecht AA;
    Haematologica; 2017 Feb; 102(2):320-326. PubMed ID: 27658438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.
    van de Loosdrecht AA; Westers TM; Westra AH; Dräger AM; van der Velden VH; Ossenkoppele GJ
    Blood; 2008 Feb; 111(3):1067-77. PubMed ID: 17971483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes.
    Goardon N; Nikolousis E; Sternberg A; Chu WK; Craddock C; Richardson P; Benson R; Drayson M; Standen G; Vyas P; Freeman S
    Haematologica; 2009 Aug; 94(8):1160-3. PubMed ID: 19644143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes.
    Sandes AF; Yamamoto M; Matarraz S; Chauffaille Mde L; Quijano S; López A; Oguro T; Kimura EY; Orfao A
    Haematologica; 2012 Jun; 97(6):895-902. PubMed ID: 22271903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplastic syndrome: validation of flow cytometry multilineage score system.
    Araújo HV; Correia RP; Bento LC; Vaz ADC; Sousa FA; Alexandre AM; Schimidell D; Pedro EC; Ioshida MR; Barroso RS; Bacal NS
    Einstein (Sao Paulo); 2020; 18():eAO4966. PubMed ID: 31994605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes.
    Ogata K; Kishikawa Y; Satoh C; Tamura H; Dan K; Hayashi A
    Blood; 2006 Aug; 108(3):1037-44. PubMed ID: 16574954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes.
    Cherian S; Moore J; Bantly A; Vergilio JA; Klein P; Luger S; Bagg A
    Cytometry B Clin Cytom; 2005 Mar; 64(1):9-17. PubMed ID: 15668954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy.
    Shameli A; Dharmani-Khan P; Luider J; Auer I; Shabani-Rad MT
    Cytometry B Clin Cytom; 2021 Sep; 100(5):574-589. PubMed ID: 33369070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic application and clinical significance of FCM progress scoring system based on immunophenotyping in CD34+ blasts in myelodysplastic syndromes.
    Xu F; Guo J; Wu LY; He Q; Zhang Z; Chang CK; Li X
    Cytometry B Clin Cytom; 2013; 84(4):267-78. PubMed ID: 23554290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.